Literature DB >> 16377260

Calpain 10 and development of diabetes mellitus in cystic fibrosis.

Salma Derbel1, Celine Doumaguet, Dominique Hubert, Helene Mosnier-Pudar, Sophie Grabar, Jamel Chelly, Thierry Bienvenu.   

Abstract

Diabetes mellitus (DM) and abnormal glucose tolerance (IGT) are common in cystic fibrosis (CF). The loss of pancreatic beta-cells due to pancreatic fibrosis is thought to be one of the principal causes of diabetes in CF, but the aetiology of DM remains somewhat puzzling. Genetic factors may contribute to the development of CF related diabetes (CFRD). The purpose of this study was to investigate the role of polymorphisms in six genes on IGT or DM incidence. PCR and dHPLC were used to screen DNA samples for polymorphisms. Using 2-h oral glucose tolerance tests, 163 adult pancreatic insufficient CF patients have been subdivided in 3 groups: 54 NGT (normal glucose tolerance), 33 IGT and 76 CFRD. We found the first evidence for the association between CFRD and UCSNP-19 polymorphism in the CAPN10 gene. The UCSNP-19 genotype distribution differed significantly between NGT, IGT and CFRD groups. The difference reflected an increase in the 22 genotype (3 copies of 32-bp sequence) in IGT and CFRD patients (p=0.05). Odds ratio for the homozygote 22 versus homozygote 11 was 3.4 (p=0.02). All allele and genotype distributions for the other polymorphisms were similar in the three groups. In conclusion, our observations suggest that UCSNP-19 of CAPN10 may be involved in the pathogenesis of diabetes in CF.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16377260     DOI: 10.1016/j.jcf.2005.09.011

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  10 in total

1.  The influence of genetics on cystic fibrosis phenotypes.

Authors:  Michael R Knowles; Mitchell Drumm
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

2.  Role of Calpain in Pathogenesis of Human Disease Processes.

Authors:  Brittany A Potz; M Ruhul Abid; Frank W Sellke
Journal:  J Nat Sci       Date:  2016

Review 3.  Update on gene modifiers in cystic fibrosis.

Authors:  Joseph M Collaco; Garry R Cutting
Journal:  Curr Opin Pulm Med       Date:  2008-11       Impact factor: 3.155

Review 4.  Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review.

Authors:  Antoinette Moran; Dorothy Becker; Samuel J Casella; Peter A Gottlieb; M Sue Kirkman; Bruce C Marshall; Bonnie Slovis
Journal:  Diabetes Care       Date:  2010-12       Impact factor: 19.112

Review 5.  Diagnosis and treatment of endocrine comorbidities in patients with cystic fibrosis.

Authors:  Oranan Siwamogsatham; Jessica A Alvarez; Vin Tangpricha
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2014-10       Impact factor: 3.243

6.  Tau phosphorylation and μ-calpain activation mediate the dexamethasone-induced inhibition on the insulin-stimulated Akt phosphorylation.

Authors:  Yudong Liu; Ying Su; Shenggang Sun; Tao Wang; Xian Qiao; Xiaoqin Run; Zhihou Liang
Journal:  PLoS One       Date:  2012-04-20       Impact factor: 3.240

7.  Effect of exercise training on calpain systems in lean and obese Zucker rats.

Authors:  Yao-Yuan Hsieh; Chi-Chen Chang; Kung-Hao Hsu; Fuu-Jen Tsai; Chih-Ping Chen; Horng-Der Tsai
Journal:  Int J Biol Sci       Date:  2008-09-09       Impact factor: 6.580

8.  Evaluation of a five-year predicted survival model for cystic fibrosis in later time periods.

Authors:  Theodore G Liou; Christiana Kartsonaki; Ruth H Keogh; Frederick R Adler
Journal:  Sci Rep       Date:  2020-04-20       Impact factor: 4.379

Review 9.  Cystic Fibrosis-Related Diabetes (CFRD): Overview of Associated Genetic Factors.

Authors:  Fernanda Iafusco; Giovanna Maione; Francesco Maria Rosanio; Enza Mozzillo; Adriana Franzese; Nadia Tinto
Journal:  Diagnostics (Basel)       Date:  2021-03-22

Review 10.  Disease-modifying genes and monogenic disorders: experience in cystic fibrosis.

Authors:  Sabina Gallati
Journal:  Appl Clin Genet       Date:  2014-07-10
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.